The Use of Nafamostat Mesilate as an Anticoagulant during Continuous Renal Replacement Therapy for Children with a High Risk of Bleeding = 출혈성 경향이 높은 소아환자의 지속성 신대체 요법시 사용되는 항응고제로서 Nafamostat mesilate의 사용

다국어 초록 (Multilingual Abstract)

Purpose: Nafamostat mesilate (NM), a synthetic serine protease inhibitor, has been investigated as an anticoagulant for adult patients with a high risk of bleeding, who need chronic renal replacement therapy (CRRT). However, little is known about the use of NM as an anticoagulant in pediatric CRRT. The aim of this study was to evaluate the ideal dosage, efficacy, and safety of NM in pediatric CRRT. Methods: We conducted a retrospective study of 40 pediatric patients who had undergone at least 24 h of venovenous CRRTs between January 2011 and October 2013. We divided the patients according to risk of bleeding. Those at high risk received no anticoagulation (group 1) or NM as an anticoagulant (group 2), while those at low risk received heparin (group 3). Results: Forty patients (25 male and 15 female; mean age, $8.2{\pm}6.6$ years) were enrolled. The mean duration of CRRT was 13.0 days, and the survival rate was 57.5%. The mean hemofilter lifespan was 39.3 h in group 1 and 11.3 h in group 3. In group 2, hemofilter lifespan was extended from 7.5 h to 27.4 h after the use of NM (P =0.001). The mean hemofilter lifespan with NM was greater than with heparin (P =0.018). No patient experienced a major bleeding event during treatment with NM. Conclusion: NM may be a good alternative anticoagulant in pediatric patients with a high risk of bleeding requiring CRRT, and is not associated with bleeding complications.

참고문헌 (Reference)

1 Ronco C, "Treatment of acute renal failure in newborns by continuous arteriovenous hemofiltration" 29 : 908-915, 1986

2 Hu ZJ, "Time course of activated coagulation time at various site during continuous hemodiafiltration using nafamostat mesilate" 25 : 524-527, 1999

3 Baek NN, "The role of nafamostat mesylate in continuous renal replacement therapy among patients at high risk of bleeding" 34 : 279-285, 2012

4 Yang JW, "Superior outcome of nafamostat mesilate as an anticoagulant in patients undergoing maintenance hemodialysis with intracerebral hemorrhage" 31 : 668-675, 2009

5 Yamazato M, "Severe abdominal pain associated with allergic reaction to nafamostat mesilate in a chronic hemodialsysis patient" 41 : 864-866, 2002

6 Ohtake Y, "Nafamostat mesylate as anticoagulant in continuous hemofiltration and continuous hemidiafiltration" 93 : 215-217, 1991

7 Maruyama Y, "Nafamostat mesilate as an anticoagulation during continuous veno-venous hemodialysis: a three-year retrospective cohort study" 34 : 571-576, 2011

8 Vasudevan A, "Modality of choice for renal replacement thepray for children with acute kidney injury: Results of a survey" 22 : 121-124, 2012

9 Muto S, "Mechanisms of hyperkalemia caused by nafamostat mesilate" 26 : 1627-1632, 1995

10 Davis H, "Maintaining the CRRT circuit: non-anticoagulant alternatives" 19 : 133-138, 2006

11 Kammerl MC, "Extracorporal therapy with AN 69 membranes in combination with ACE inhibiton causing severe anaphylactoid reactions:still a current problem?" 53 : 486-486, 2000

12 Scott Walters, "Dialysis and pediatric acute kidney injury: choice of renal support modality" 24 : 37-48, 2009

13 Hiroma T, "Continuous venovenous hemofiltration in neonatal onset hyperammonemia" 19 : 221-224, 2002

14 Scott M, "Continuous renal replacement therapy in children" 27 : 2007-2016, 2012

15 Michael Joannidis, "Clinical review: Patency of the circuit in continuous renal replacement therapy" 11 : 218-, 2007

16 Flynn JT, "Choice of dialysis modality for management of pediatric acute renal failure" 17 : 61-69, 2002

17 Kramer P, "Arteriovenous haemofilteration: A new and simple method for treatment of over-hydrated patients resistant to diuretics" 55 : 1121-1122, 1997

18 Nagava M, "Application of a new anticoagulant (Nafamostat mesilate) to control hemorrhagic complications during extracorporeal membrane oxygenation-a preliminary report" 32 : 531-535, 1997

19 R. L. Mehta, "Anticoagulation in severely ill patients treated with continuous hemofiltration" 12 : 287-294, 1992

20 Tolwani AJ, "Anticoagulation for continuous renal replacement therapy" 22 : 141-145, 2009

21 Maruyama H, "Anaphylactoid reaction induced by nafamostat mesilate in a hemodialysis patient" 74 : 468-469, 1996

22 Higuchi N, "Anaphylactoid reaction induced by a protease inhibitor, nafamostat mesilate, following nine administrations in a hemodialysis patient" 85 : 400-401, 2000

23 Davenport A, "Alternatives to standard unfractionated heparin for pediatric hemodialysis treatments" 27 : 1869-1879, 2012

24 Ookawara S, "Additional mechanisms of nafamostat mesilate-associated hyperkalemia" 51 : 149-151, 1996